JPWO2020172450A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172450A5 JPWO2020172450A5 JP2021548668A JP2021548668A JPWO2020172450A5 JP WO2020172450 A5 JPWO2020172450 A5 JP WO2020172450A5 JP 2021548668 A JP2021548668 A JP 2021548668A JP 2021548668 A JP2021548668 A JP 2021548668A JP WO2020172450 A5 JPWO2020172450 A5 JP WO2020172450A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024139367A JP2024164116A (ja) | 2019-02-20 | 2024-08-21 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| US62/808,141 | 2019-02-20 | ||
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139367A Division JP2024164116A (ja) | 2019-02-20 | 2024-08-21 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520868A JP2022520868A (ja) | 2022-04-01 |
| JPWO2020172450A5 true JPWO2020172450A5 (enExample) | 2023-02-27 |
| JP7543290B2 JP7543290B2 (ja) | 2024-09-02 |
Family
ID=69844940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548668A Active JP7543290B2 (ja) | 2019-02-20 | 2020-02-20 | 抗ｔｒｅｍ２抗体及びその使用方法 |
| JP2024139367A Pending JP2024164116A (ja) | 2019-02-20 | 2024-08-21 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139367A Pending JP2024164116A (ja) | 2019-02-20 | 2024-08-21 | 抗ｔｒｅｍ２抗体及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220073609A1 (enExample) |
| EP (1) | EP3927743A1 (enExample) |
| JP (2) | JP7543290B2 (enExample) |
| KR (1) | KR20210135518A (enExample) |
| CN (1) | CN113614110B (enExample) |
| AR (1) | AR118144A1 (enExample) |
| AU (1) | AU2020226754A1 (enExample) |
| BR (1) | BR112021015656A2 (enExample) |
| CA (1) | CA3130086A1 (enExample) |
| CL (1) | CL2021002206A1 (enExample) |
| CO (1) | CO2021012230A2 (enExample) |
| EA (1) | EA202192294A1 (enExample) |
| EC (1) | ECSP21069105A (enExample) |
| IL (1) | IL285651A (enExample) |
| MA (1) | MA55025A (enExample) |
| MX (1) | MX2021009722A (enExample) |
| PE (1) | PE20211979A1 (enExample) |
| PH (1) | PH12021552002A1 (enExample) |
| SG (1) | SG11202108734VA (enExample) |
| TW (1) | TWI879756B (enExample) |
| WO (2) | WO2020172450A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| PE20211474A1 (es) * | 2018-12-18 | 2021-08-05 | Boehringer Ingelheim Io Canada Inc | Anticuerpos agonistas de flt3 y usos de estos |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| CN115279790A (zh) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| TW202306993A (zh) * | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Ｔｒｅｍ２之促效劑 |
| EP4482523A1 (en) | 2022-02-23 | 2025-01-01 | Alector LLC | Methods of use of anti-trem2 antibodies |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| EP4658684A1 (en) | 2023-01-30 | 2025-12-10 | ISAR Bioscience GmbH | Human anti-trem2 antibody for treating neurodegenerative disorders |
| WO2025032071A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025106361A1 (en) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Human nectin-4 binders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| CN102272300A (zh) | 2009-01-06 | 2011-12-07 | 雀巢产品技术援助有限公司 | 常量营养物的加工 |
| TW201613969A (en) | 2009-03-05 | 2016-04-16 | Abbvie Inc | IL-17 binding proteins |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| KR20140033152A (ko) * | 2011-06-20 | 2014-03-17 | 교와 핫꼬 기린 가부시키가이샤 | 항erbB3 항체 |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| WO2015033223A2 (en) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| MX2017001531A (es) * | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| US10428143B2 (en) | 2014-09-28 | 2019-10-01 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| EP3277305B1 (en) | 2015-03-31 | 2021-07-21 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US10941200B2 (en) | 2016-07-22 | 2021-03-09 | Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev | TREM2 cleavage modulators and uses thereof |
| CN110121507B (zh) | 2016-12-23 | 2024-04-05 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| EP3570883A2 (en) | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| AU2018307877A1 (en) | 2017-07-27 | 2020-01-02 | Novartis Ag | Sheddase resistant TREM2 variants |
| RS64419B1 (sr) * | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 antitela i postupci za njihovu upotrebu |
| ES2956062T3 (es) | 2017-08-10 | 2023-12-12 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados por ingeniería |
| US20200277373A1 (en) | 2017-09-14 | 2020-09-03 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| SG11202002730XA (en) | 2017-10-02 | 2020-04-29 | Denali Therapeutics Inc | Fusion proteins comprising enzyme replacement therapy enzymes |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES |
| TW201934573A (zh) | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| AU2019288212A1 (en) | 2018-06-18 | 2020-12-03 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| CN112839955A (zh) | 2018-08-16 | 2021-05-25 | 戴纳立制药公司 | 经工程改造双特异性蛋白 |
| WO2020041604A1 (en) | 2018-08-22 | 2020-02-27 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
| CN113826015A (zh) | 2018-12-10 | 2021-12-21 | 戴纳立制药公司 | 溶酶体贮积症的生物标志物及其使用方法 |
| US12351629B2 (en) | 2018-12-10 | 2025-07-08 | Mor Research Applications Ltd. | TREM2 antibodies and uses thereof |
| CN113194994B (zh) | 2018-12-11 | 2025-11-28 | 开拓免疫医疗公司 | 使用抗trem2抗体的方法 |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| KR20220004651A (ko) | 2019-04-03 | 2022-01-11 | 데날리 테라퓨틱스 인크. | 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제 |
| KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| CN115279790A (zh) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| BR112022016232A2 (pt) | 2020-02-19 | 2022-11-16 | Denali Therapeutics Inc | Proteínas biespecíficas anti-her2 manipuladas |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
-
2020
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko active Pending
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
-
2021
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP2024164116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220089748A1 (en) | Pdgf receptor beta binding polypeptides | |
| EP3458479B1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| AU2009245354B2 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2020517249A5 (enExample) | ||
| US12157765B2 (en) | Modified immunoglobulins for targeting amyloid deposits | |
| JP2024056687A5 (enExample) | ||
| JPWO2020172450A5 (enExample) | ||
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| TW201138825A (en) | TNF-α binding proteins | |
| PH12014501682B1 (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| JPWO2021146256A5 (enExample) | ||
| TW201134489A (en) | Basigin binding proteins | |
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| JP2025507938A (ja) | 抗ｐｄ－ｌ２抗体 | |
| JP6231632B2 (ja) | Ａｎｇ２抗体 | |
| JP2023531822A (ja) | タウ結合分子 | |
| CN117279944A (zh) | 干细胞因子抗体及其使用方法 | |
| CN116368153A (zh) | Zip12抗体 | |
| CA2538725A1 (en) | Nogo-a binding molecules and pharmaceutical use thereof | |
| JPWO2021097360A5 (enExample) | ||
| WO2025228315A1 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| WO2025228316A1 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| US20170183401A1 (en) | Hypoglycemic agent containing anti-ang2 antibody | |
| EA048681B1 (ru) | Модифицированные иммуноглобулины для нацеливания на амилоидные отложения |